Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV140 in women with RUTI
NCT02543827Phase 3Completed
- Sponsor
- Inmunotek
- Start
- Nov 2015
- Primary completion
- Nov 2020
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of MV140 in urinary tract infection (UTI) (3 arms), sponsored by Inmunotek. Primary endpoint: Decrease in the number of RUTI exacerbations at 1 year. Started Nov 2015; status: completed.
02
Drugs
MV140
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT02543827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543827.